

## REMARKS

### 1. Formal Matters

#### a. Status of the Claims

Claims 1-17 are pending in this application. Applicant hereby cancels claims 1-17 without prejudice to pursuing the canceled subject matter in a continuing application, and claims 18-29 are new. Applicant respectfully requests entry of the amendments and remarks made herein into the file history of the instant application. Upon entry of these amendments, claims 18-29 will be pending and under active consideration.

#### b. Amendments to the Claims

Support for new claims 18-29 can be found throughout the application as originally filed, for example as shown in the table below.

Amended Claim	Support in Application
18	Table 2, lines 930180-930271 Table 6, lines 1900804-1900808 and 1900884-1900888 Paragraphs 0041, 0043, and 0044
19	See claim 18 above and Table 1, line 17532
20	See claim 18 above and paragraph 0047
21	See claim 18 above
22	See claims 18 and 21 above
23	See claims 18, 19, and 21 above
24	See claim 18 above and paragraph 0042
25	See claim 19 above and paragraph 0042
26	See claim 20 above and paragraph 0042
27	See claim 21 above and paragraph 0042
28	See claim 22 above and paragraph 0042
29	See claim 23 above and paragraph 0042

### 2. Election/Restrictions

#### a. Restriction to an Invention Group

On pages 2-4 of the Office Action, the Examiner requires restriction to one of the following inventions under 35 U.S.C. § 121:

- I. Claims 1-16, drawn to a bioinformatically detectable endogenously processed oligonucleotide that represses expression of a target mRNA.
- II. Claim 17, drawn to a method for detecting microRNAs.

Applicant without traverse elects Group I, which is considered claims 18-29.

### b. Restriction to One Sequence

On pages 4 and 5 of the Office Action, the Examiner further requires restriction to one sequence under 35 U.S.C. § 121 and 37 C.F.R. § 1.141. Applicant without traverse elects nucleic acids related to SEQ ID NO: 2240728, which is associated with claims 18-29. Applicant notes that the elected sequence comprises SEQ ID NO: 8385 as shown below.

SEQ ID NO: 2240728 TCTCAAGCTGTGACTGCAAAGGGAAGCCCTTTCTGTTGCTCAAAAGAAAAAGTGCCTTCCCTTTGGTGAATTACGGTTTGAGA  
SEQ ID NO: 8385 AGAAAGTGCCTTCCCTTTGGTGA

### 3. Conclusion

Applicant respectfully submits that this application is in good and proper order for substantive examination.

Respectfully submitted,

POLSINELLI SHALTON FLANIGAN SUELTHAUS PC

Dated: October 25, 2007

On behalf of: Teddy C. Scott, Jr., Ph.D.  
Registration No. 53,573

By: /Ron Galant, Ph.D./  
Ron Galant, Ph.D.  
Registration No. 60,558  
Customer No. 37808

POLSINELLI SHALTON FLANIGAN SUELTHAUS PC  
180 N. Stetson Ave., Suite 4525  
Chicago, IL 60601  
312.819.1900 (main)  
312.602.3955 (E-fax)  
312.873.3613 (direct)